{
    "root": "88320064-2e30-4866-9174-02d1aa521c73",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ondansetron",
    "value": "20250306",
    "ingredients": [
        {
            "name": "ONDANSETRON HYDROCHLORIDE",
            "code": "NMH84OZK2B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7774"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30769"
        },
        {
            "name": "TRISODIUM CITRATE DIHYDRATE",
            "code": "B22547B95K"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "ondansetron injection 5-ht 3 receptor antagonist indicated prevention : \u2022 nausea vomiting associated initial repeat courses emetogenic cancer chemotherapy . ( 1.1 ) \u2022 postoperative nausea and/or vomiting . ( 1.2 )",
        "doid_entities": [
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "prevention nausea vomiting associated initial repeat courses emetogenic cancer chemotherapy ( 2.1 ) : \u2022 dilution ondansetron injection 50 ml 5 % dextrose injection 0.9 % sodium chloride injection required adult pediatric patients . \u2022 adults pediatric patients 6 months age older : recommended 0.15 mg/kg per dose 3 doses ( maximum 16 mg per dose ) , infused intravenously 15 minutes . \u2022 administer first dose 30 minutes start chemotherapy subsequent doses 4 8 hours first dose . prevention postoperative nausea and/or vomiting ( 2.2 ) : \u2022 dilution ondansetron injection required adult pediatric patients . \u2022 full prescribing information recommended instructions adult pediatric patients 1 month age older . patients severe hepatic impairment ( 2.3 ) : \u2022 exceed total daily dose 8 mg .",
        "doid_entities": [
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "ondansetron injection , usp , 2 mg/ml , supplied follows : unit sale concentration ndc 0409-0009-25 tray 252 ml single-dose vials 4 mg/2 ml ( 2 mg/ml )",
    "adverseReactions": "ondansetron injection contraindicated patients known hypersensitivity ( e.g . , anaphylaxis ) product components . anaphylactic reported patients taking ondansetron [ ( 6.2 ) ] . concomitant apomorphine ondansetron contraindicated based reports profound hypotension loss consciousness apomorphine administered ondansetron .",
    "indications_original": "Ondansetron Injection is a 5-HT 3 receptor antagonist indicated for the prevention of: \u2022 nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. ( 1.1 ) \u2022 postoperative nausea and/or vomiting. ( 1.2 )",
    "contraindications_original": "Prevention of Nausea and Vomiting Associated With Initial and Repeat Courses of Emetogenic Cancer Chemotherapy ( 2.1 ): \u2022 Dilution of Ondansetron Injection in 50 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection is required before administration to adult and pediatric patients. \u2022 Adults and pediatric patients 6 months of age and older: The recommended dosage is 0.15 mg/kg per dose for 3 doses (maximum of 16 mg per dose), infused intravenously over 15 minutes. \u2022 Administer the first dose 30 minutes before the start of chemotherapy and subsequent doses 4 and 8 hours after the first dose. Prevention of Postoperative Nausea and/or Vomiting ( 2.2 ): \u2022 Dilution of Ondansetron Injection is not required before administration to adult and pediatric patients. \u2022 See full prescribing information for the recommended dosage and administration instructions for adult and pediatric patients 1 month of age and older. Patients With Severe Hepatic Impairment ( 2.3 ): \u2022 Do not exceed a total daily dose of 8 mg.",
    "warningsAndPrecautions_original": "Ondansetron Injection, USP, 2 mg/mL, is supplied as follows:\n                  \n                     \n                     \n                     \n                        \n                           \n                              Unit of Sale\n                           \n                           \n                              Concentration\n                           \n                        \n                     \n                     \n                        \n                           \n                              \n                                 NDC 0409-0009-25\n                                 Tray of 252 mL Single-dose Vials\n                           \n                           \n                              4 mg/2 mL(2 mg/mL)",
    "adverseReactions_original": "Ondansetron Injection is contraindicated for patients known to have hypersensitivity (e.g., anaphylaxis) to this product or any of its components. Anaphylactic reactions have been reported in patients taking ondansetron [see Adverse Reactions (6.2)].\n                  The concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron.",
    "drug": [
        {
            "name": "Ondansetron",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7773"
        }
    ]
}